

# MM01

## Molecular Testing for Heritable Genetics and Specimen Identification

This guideline provides recommendations for detecting and reporting genetic variation associated with heritable conditions.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

---

# Molecular Testing for Heritable Genetics and Specimen Identification

Lawrence J. Jennings, MD, PhD, D(ABHI), FCAP  
Alexander Craig Mackinnon, Jr., MD, PhD  
Heddie L. Nichols, PhD  
Arunkanth Ankala, MSc, PhD, FACMG  
Yang Cao, PhD, FACMG, DABMGG  
Kristen Champion, PhD, FACMG  
Basil Elyas, PMP, CSSBB, BSc, MSc  
Robin E. Everts, PhD  
Tracey Freitas, MS, PhD  
Julie Gastier-Foster, PhD, FACMG  
Susan J. Hsiao, MD, PhD  
Alexander Ing, MS, CGC  
Jamey Kain, PhD  
Katrin Leuer, PhD

Marco L. Leung, PhD, FACMG  
Dawn Maghakian, MS, MB(ASCP)<sup>CM</sup>, CGMBS  
Lindsey Mighion, MS, CGC  
Gwyneth K. Olson, BS, M.Phil, MB(ASCP)<sup>CM</sup>  
Cynthe Sims, PhD, HCLD(ABB)  
Elizabeth Spiteri, PhD, FACMG  
Colleen Stevens, PhD  
Alan Stuart, BSc, MLT  
Madina Sukhanova, PhD, FACMG  
Felicidad Valcarcel, BS, MS  
Richard Y. Wang, DO  
Kai Lee Yap, PhD, FACMG  
Yiyong Zhou, PhD  
Val V. Zvereff, MD, PhD, FACMG

## Abstract

---

Clinical and Laboratory Standards Institute guideline MM01—*Molecular Testing for Heritable Genetics and Specimen Identification* provides general recommendations for all phases of the operation of a molecular diagnostic laboratory focused on detecting and reporting genetic variation associated with heritable conditions. It explains different types of genetic variation, along with the corresponding standardized nomenclature. Various methods of detecting and characterizing genetic variants are described, as well as test-specific requirements for validation and quality assurance. This guideline also discusses special considerations for analyzing and reporting genetic variation associated with heritable conditions.

Clinical and Laboratory Standards Institute (CLSI). *Molecular Testing for Heritable Genetics and Specimen Identification*. 4th ed. CLSI guideline MM01 (ISBN 978-1-68440-189-5 [Print]; ISBN 978-1-68440-190-1 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2023 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Molecular Testing for Heritable Genetics and Specimen Identification*. 4th ed. CLSI guideline MM01. Clinical and Laboratory Standards Institute, USA, 2023.

### Previous Editions:

December 1997, April 2000, June 2006, May 2012

MM01-Ed4

ISBN 978-1-68440-189-5 (Print)

ISBN 978-1-68440-190-1 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 43, Number 13

.....

## Committee Membership

### Consensus Council

The Consensus Council sets priorities for CLSI standards development and votes on Final Draft documents to confirm that process requirements have been met. Consensus Council members are listed on the CLSI website: <https://clsi.org/standards-development/consensus-council/>

### Document Development Committee on Molecular Methods for Clinical Genetics and Identity Testing

**Lawrence J. Jennings, MD, PhD,  
D(ABHI), FCAP  
Chairholder  
Northwestern University  
USA**

Kristen Champion, PhD, FACMG  
Quest Diagnostics  
USA

Gwyneth K. Olson, BS, M.Phil,  
MB(ASCP)<sup>CM</sup>  
Tricore Reference Laboratories  
USA

**Alexander Craig Mackinnon, Jr., MD,  
PhD  
Vice-Chairholder  
University of Alabama at  
Birmingham  
USA**

Robin E. Everts, PhD  
Agena Bioscience  
USA

Elizabeth Spiteri, PhD, FACMG  
Stanford University - School of  
Medicine  
USA

**Heddie L. Nichols, PhD  
Committee Secretary  
Genentech via Ascent  
USA**

Julie Gastier-Foster, PhD, FACMG  
Texas Children's Hospital  
USA

Colleen Stevens, PhD  
New York State Department of Health  
Wadsworth Center  
USA

Yang Cao, PhD, FACMG, DABMGG  
Washington University in St. Louis,  
School of Medicine  
USA

Katrin Leuer, PhD  
Ann & Robert H. Lurie Children's  
Hospital of Chicago  
USA

Felicidad Valcarcel, BS, MS  
Centers for Medicare & Medicaid  
Services  
USA

Dawn Maghakian, MS, MB(ASCP)<sup>CM</sup>,  
CGMBS  
USA

Val V. Zvereff, MD, PhD, FACMG  
National Reference Laboratory  
United Arab Emirates

### Expert Panel on Quality Management Systems

Expert panel volunteers support the development of CLSI documents by providing technical expertise in specialty areas. Expert panel members are listed by area of expertise on the CLSI website: <https://clsi.org/standards-development/expert-panels/>

### Staff

Clinical and Laboratory Standards  
Institute  
USA

Katherine Castagna, MS, MLS(ASCP)  
CT, MB  
*Program Manager*

Kristy L. Leirer, MS  
*Editor*

Emily J. Gomez, MS, MLS(ASCP)<sup>CM</sup>MB<sup>CM</sup>  
*Program Manager*

Laura Martin  
*Editorial Manager*

Lisa M.W. Walker, MS, ELS  
*Editor*

DeeDee P. Meadows, MLS(ASCP)MB  
*Program Manager*

Catherine E.M. Jenkins, ELS  
*Editor*

## Acknowledgment

---

CLSI, the Consensus Council, and the Document Development Committee on Molecular Methods for Clinical Genetics and Identity Testing gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

Arunkanth Ankala, MSc, PhD, FACMG  
Emory University School of Medicine  
USA

Jamey Kain, PhD  
Machaon Diagnostics, Inc.  
USA

Madina Sukhanova, PhD, FACMG  
Northwestern University  
USA

Basil Elyas, PMP, CSSBB, BSc, MSc  
Alberta Health Services  
Canada

Marco L. Leung, PhD, FACMG  
Nationwide Children's Hospital  
USA

Richard Y. Wang, DO  
Centers for Disease Control and  
Prevention  
USA

Tracey Freitas, MS, PhD  
Quest Diagnostics  
USA

Lindsey Mighion, MS, CGC  
GeneDx  
USA

Kai Lee Yap, PhD, FACMG  
Ann & Robert H. Lurie Children's  
Hospital of Chicago  
USA

Susan J. Hsiao, MD, PhD  
Columbia University Medical Center  
USA

Cynthe Sims, PhD, HCLD(ABB)  
Torreyana Corporation  
USA

Yiyong Zhou, PhD  
Roche Molecular Systems, Inc.  
USA

Alexander Ing, MS, CGC  
Ann & Robert H. Lurie Children's  
Hospital of Chicago  
USA

Alan Stuart, BSc, MLT  
London Health Sciences Centre  
Canada

# Contents

Abstract	i
Committee Membership	iii
Foreword	vii
<b>Chapter 1: Introduction</b>	<b>1</b>
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	3
1.4 Terminology	3
<b>Chapter 2: Path of Workflow</b>	<b>13</b>
<b>Chapter 3: Genetic Variation and Nomenclature</b>	<b>15</b>
3.1 Overview of Genetic Variation	16
3.2 Chromosomal and Structural Variants	16
3.3 Nucleotide Variants	23
3.4 Mitochondrial DNA Variants and Heteroplasmy	31
3.5 Epigenetics	35
<b>Chapter 4: Methods for Detection of Genetic Variation</b>	<b>37</b>
4.1 Overview of Molecular Methods	38
4.2 Methods to Detect Chromosomal and Structural Variants	42
4.3 Methods to Detect Nucleotide Variants	45
4.4 RNA Analysis	61
4.5 Methylation Analysis	62
<b>Chapter 5: Analytical Validation, Clinical Validation, and Clinical Utility</b>	<b>65</b>
5.1 Overview	66
5.2 Analytical Validation	67
5.3 Clinical Validation	72
5.4 Clinical Utility	78
<b>Chapter 6: Quality System Essentials</b>	<b>79</b>
6.1 Quality System Components of Molecular Testing	80
6.2 Laboratory-Developed Test Considerations	82
6.3 Appropriate and Actionable Quality Control Monitoring	84
6.4 Continual Improvement	87

# Contents (Continued)

<b>Chapter 7: Preexamination</b>	<b>91</b>
7.1 Considerations for Genetic Testing: Ethical, Privacy, and Financial	92
7.2 Preexamination Genetic Consultation	93
7.3 Specimen Collection, Transport, Storage, and Tracking	96
7.4 Specimen Accessioning	99
7.5 Sample Processing	101
7.6 Sample Storage and Retention	103
7.7 Preexamination Quality Considerations	103
<b>Chapter 8: Examination</b>	<b>105</b>
8.1 Process Control	106
8.2 Provenance Testing	107
8.3 Analysis and Interpretation of Sequence Variants	109
8.4 Bioinformatics Pipeline	110
<b>Chapter 9: Postexamination</b>	<b>115</b>
9.1 Laboratory Records of Molecular Test Results	116
9.2 Laboratory Reports for Molecular Tests	117
9.3 Confidentiality of Molecular Laboratory Reports	120
9.4 Retention and Security of Molecular Laboratory Records	121
9.5 Duty to Reanalyze and Recontact After Issuing Molecular Reports	122
9.6 Postexamination Genetic Consultation	124
9.7 Sample Retention for Molecular Testing	124
9.8 Data Management for Molecular Testing	125
<b>Chapter 10: Conclusion</b>	<b>127</b>
<b>Chapter 11: Supplemental Information</b>	<b>129</b>
<b>References</b>	130
<b>Appendix A.</b> Example of a Failure Modes and Effects Analysis	147
<b>Appendix B.</b> Bayesian Calculations	153
<b>Appendix C.</b> Molecular Genetic Report Examples	156
<b>The Quality Management System Approach</b>	160

## Foreword

Profound technical advances in data acquisition and data analysis have propelled clinical genetic testing to the forefront of laboratory medicine and delivered the era of precision medicine. As a result, many medical laboratories routinely interrogate the entire genome to screen for, monitor, and/or diagnose health disorders; assess well-being; and treat medical conditions. The success of modern genetic testing relies on the proper use of complex analytics and bioinformatics.

This edition of MM01 focuses exclusively on genetic variation associated with heritable conditions. It is intended for use by laboratory staff who oversee all clinical, scientific, and/or operational aspects of the molecular laboratory. Individuals in these roles are responsible for introducing, developing, validating, implementing, and interpreting laboratory tests in the safest, most efficient, and most cost-effective manner possible. To this end, MM01 includes guidance on maintaining the highest standards of quality through robust QC systems.

### Overview of Changes

This guideline replaces the previous edition of the approved guideline, MM01-A3, published in 2012. Several changes were made in this edition, including:

- Removing information on oncology markers and somatic or acquired genetic signatures associated with nonhematological cancers
  - See CLSI documents MM05,<sup>1</sup> MM21,<sup>2</sup> and MM23<sup>3</sup> for information on these topics.
- Updating the types of heritable genetic variation and nomenclature, including mitochondrial and epigenetic disorders (see CLSI document MM09<sup>4</sup>)
- Revising methods and technologies, including next-generation sequencing for detection of genetic variation
- Updating considerations for preexamination, examination, and postexamination processes, with a focus on challenges posed by rare, heritable diseases
- Adding special considerations for accurate reporting and interpretation of carrier screening and noninvasive prenatal testing
- Adding special considerations for bioinformatics and genetic counseling

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

#### KEY WORDS

cytogenetics

genetic variation

next-generation sequencing

epigenetics

methylation

nucleic acid

genetic disease

molecular diagnostic test

This page is intentionally left blank.

# Chapter ①

## Introduction

# Molecular Testing for Heritable Genetics and Specimen Identification

---

## 1 Introduction

### 1.1 Scope

This guideline has been revised by experienced molecular laboratory professionals to focus on germline genetic diagnostic testing. It provides information for laboratories implementing molecular assays for inherited disorders, including both distributed test systems authorized by applicable regulatory agencies and complex laboratory-developed tests (LDTs). This guideline is intended for use by experienced laboratory directors, supervisors, and manufacturers involved in assay development, validation, verification, and interpretation of molecular testing.

Because molecular diagnostics is multidisciplinary in nature, this guideline provides an overview of the subspecialties that use similar technology or performance specification details. New to this edition are clinical applications of genetic identity testing. These applications include monitoring bone marrow transplant engraftment in hematopoietic stem cell transplantation, tracing sample provenance, and detecting sample contamination. Owing to advances in preimplantation diagnostics and prenatal testing, descriptions of noninvasive and cell-free DNA (cfDNA) detection methods are included.

This guideline does not cover biochemical genetics, paternity and forensics testing, blood banking, or detection of bioterrorism agents that require biosafety levels 3 or higher.

### 1.2 Background

Molecular testing has become essential for assessing a growing number of heritable disorders and pharmacogenetic responses. Genotyping can provide useful indicators of disease diagnosis, prognosis, and progression; guide treatment selection and response; and interrogate targets for gene-specific therapies. Genetic testing can be used in the prenatal setting to screen for and diagnose either suspected or at-risk disorders. In the postnatal setting, genetic testing is routinely used for newborn screening and for diagnosis of suspected disorders. In the pediatric and adult settings, in addition to diagnostics, genetic testing is used for carrier screening, presymptomatic or predictive testing, or assessment of potential treatment response.

Although sensitivity, or threshold of detection, is essential to quantitative testing for genetic signatures of acquired diseases, this guideline primarily focuses on qualitative molecular testing. CLSI document MM06<sup>5</sup> discusses quantitative molecular methods that are applicable to detecting acquired genetic variations in neoplasias, such as linearity and measuring interval, lower limit of detection (LLoD) and lower limit of quantitation, results outside the measuring interval, and technologies used in molecular quantification.

When a molecular test is performed, laboratories should consider the preexamination, examination, and postexamination factors discussed in this guideline. In addition, it is important that the test methodology and results interpretation be based on the test's indication and application. Laboratories should also consider ethical concerns associated with genetic testing and the privacy of genetic information.

Securing qualified and competent personnel at all levels is key to producing accurate and timely medical laboratory test results. Specific qualifications and responsibilities vary from region to region. However, to ensure all personnel have the appropriate skills to perform their jobs competently, medical laboratories should have